

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1: (Currently Amended) A method of detecting neuronal injury in a subject, the method comprising the steps of:

- (a) providing a blood, serum, or plasma sample from the subject;
- (b) contacting the blood, serum, or plasma sample with an antibody that specifically binds to NF-H in the sample;
- (c) detecting the presence or amount of NF-H in the sample,
wherein NF-H can be detected in quantities as low as 50 pg at a concentration of about 1 picogram/ μ l; and
- (d) correlating the presence or amount of NF-H in the sample with the neuronal injury.

Claim 2: (Canceled)

Claim 3: (Previously Presented) The method of claim 1, wherein the step (c) of detecting the presence or amount of NF-H comprises performing an immunoassay selected from the group consisting of immunoblotting, ELISA, radioimmunoassay, immunodiffusion or immunoprecipitation.

Claims 4-5: (Canceled)

Claim 6: (Previously Presented): The method of claim 3, wherein the step (c) of detecting the presence or amount of NF-H comprises performing an ELISA.

Claim 7: (Withdrawn and Currently Amended) A kit for detecting a neuronal injury in a subject, the kit comprising:

- (a) a solid substrate;
- (b) at least one antibody that binds specifically to [[an NFDPP]] NF-H in a blood, plasma, or serum sample;
- (c) an agent for detecting binding of the at least one antibody to [[the NFDPP]] NF-H in quantities as low as 50 pg; and
- (d) instructions for using the kit to detect neuronal injury in a subject.

Claim 8: (Canceled).

Claim 9: (Withdrawn and Currently Amended) The kit of claim 7, wherein the agent for detecting binding of the at least one antibody to [[the NFDPP]] NF-H comprises a chromogenic substrate molecule.

Claim 10: (Withdrawn and Currently Amended) The kit of claim 7, wherein detecting binding of the at least one antibody to [[the NFDPP]] NF-H is correlated with neuronal injury.

Claim 11: (Previously Presented) The method of claim 1, wherein the antibody is a chicken polyclonal antibody.

Claim 12: (Previously Presented) The method of claim 1, wherein step (a) of providing a blood, serum, or plasma sample from the subject is performed within a few hours of the neuronal injury.